Position: Home > News > Company News Company News

 Tuesday, October 25, 2005 


(Hong Kong, 25 October 2005) -- Leading biopharmaceutical and modernised Chinese medicine producer Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Group”; HKEx: 1177) is pleased to announce that it has made Forbes Asia’s Annual “Best 200 Under a Billion” list. The selection is mainly derived from the corporates’ proven track record and rewarding earnings performance. There are totally 11 Chinese and 22 Hong Kong public companies being named in the list, but only Sino Biopharmaceutical the Hong Kong listed pharmaceutical company. Mr. Tse Ping, Chairman of Sino Biopharmaceutical, commented on the encouraging achievement, “We are delighted that Sino Biopharmaceutical’s corporate and investment strategies are recognized by the investment community. It is our great honour to receive such prestigious acknowledgement. 


This achievement will motivate us to continuously strengthen our corporate governance, as well as our commitment to our shareholders and investors. In addition, building on our solid foundation in the domestic pharmaceutical market, we are confident of capturing every arising opportunity to grow our business and cement our industry leader position. And to ensure our long term growth, we will take advantage of the industry consolidation to identify and pursue different M&A opportunities, and ultimately create value for all our stakeholders.”


About Sino Biopharmaceutical Limited:


The Group is principally engaged in the R&D, production and sale of a series of modernised Chinese medicines, chemical medicines and modern health-care products produced by JCTT and NJCTT for treating hepatitis and angiopathy for cardio-cerebral conditions. In addition, the Group will establish a new technology development, and production and sales base in Beijing, through Beijing Tide. The Group sees new growth drivers in the utilization of nano technology in production, sales of Alprostadil intravenous injection, and co-development of new products with international research institutes. Through CTGC, it will devote R&D efforts into a series of new medicines and modern health-care products for treating cardiovascular and respiratory diseases.


For more information:
Strategic Financial Relations Limited
Madison Wai
Tel: (852) 2864 4859
Email: madison@strategic.com.hk
Fax: (852) 2804 2789


Sandra Tsui
Tel: (852) 2864 4824
Email: sandra@strategic.com.hk